(NASDAQ: RZLT) Rezolute's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Rezolute's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast RZLT's revenue for 2026 to be $168,803,654, with the lowest RZLT revenue forecast at $168,803,654, and the highest RZLT revenue forecast at $168,803,654. On average, 1 Wall Street analysts forecast RZLT's revenue for 2027 to be $2,981,801,643, with the lowest RZLT revenue forecast at $2,981,801,643, and the highest RZLT revenue forecast at $2,981,801,643.
In 2028, RZLT is forecast to generate $12,155,448,132 in revenue, with the lowest revenue forecast at $12,155,448,132 and the highest revenue forecast at $12,155,448,132.